Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vitamin Firms, Execs Agree To Price-Fixing Guilty Pleas, $33 Mil. Fines

This article was originally published in The Tan Sheet

Executive Summary

German pharmaceutical giant Merck KgaA will pay a $14 mil. criminal fine after agreeing to plead guilty to Justice Department charges that it conspired to fix the price and allocate sales volume of vitamin C from early 1991 to fall 1995, the DoJ announced May 5.

You may also be interested in...



BASF, Hoffmann-La Roche Execs Plead Guilty To Vitamin Conspiracy Charges

Three former BASF executives and a former Hoffmann-La Roche official will serve U.S. jail time and pay criminal fines after agreeing to plead guilty in Dallas federal court to charges of participating in an international vitamin price-fixing conspiracy, the Justice Department announced April 6.

Vitamin Price-Fixing $242 Mil. Class Settlement Fund Approved

A Washington, D.C. federal judge on March 28 gave final approval to a vitamin price-fixing class action settlement that is less than one-quarter the amount and scope originally announced due to the number of large companies opting out.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS091221

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel